Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MacroGenics Inc MGNX

Healthcare Biotechnology
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.


NDAQ:MGNX - Post by User

MacroGenics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(227)
•••
Post by whytestockson May 10, 2024 5:15pm
51 Views
Post# 36034547

MacroGenics (MGNX) Q1 2024 Earnings Call Transcript

MacroGenics (MGNX) Q1 2024 Earnings Call Transcript
Just In: $MGNX MacroGenics (MGNX) Q1 2024 Earnings Call Transcript2024-05-10 02:15:10 ET Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q1 2024 Earnings Call May 09, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q1 2024 Earnings Call TranscriptMGNX - MacroGenics (MGNX) Q1 2024 Earnings Call Transcript

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities